MDT
59
2
MCO
67
3
WU
36
2
HSIC
36
-9
R
67
4
QRVO
4
2
BF.B
31
2
DUK
37
2
MTCH
53
3
PEP
47
2
GIS
29
3
MCD
54
4
HUM
39
9
MLM
58
-2
DFS
60
4
CSX
57
4
TXT
59
6
AMGN
42
-5
AIV
51
4
BBY
45
3
MDT
59
2
MCO
67
3
WU
36
2
HSIC
36
-9
R
67
4
QRVO
4
2
BF.B
31
2
DUK
37
2
MTCH
53
3
PEP
47
2
GIS
29
3
MCD
54
4
HUM
39
9
MLM
58
-2
DFS
60
4
CSX
57
4
TXT
59
6
AMGN
42
-5
AIV
51
4
BBY
45
3
Financhill
Back

Stereotaxis 10K Form

Sell
47

STXS
Stereotaxis

Last Price:
1.95
Seasonality Move:
4.4%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive STXS News And Ratings

See the #1 stock for the next 7 days that we like better than STXS

STXS Financial Statistics

Sales & Book Value

Annual Sales: $26.77M
Cash Flow: $-3.11M
Price / Cash Flow: 0
Annual Sales: $0.14
Price / Book: 14.54

Profitability

EPS (TTM): -0.26000
Net Income (TTM): $-20.75M
Gross Margin: $14.86M
Return on Equity: -94.33%
Return on Assets: -49.35%

Stereotaxis Earnings Forecast

Key Stereotaxis Financial Ratios

  • The Gross Profit Margin over the past 24 years for STXS is 55.51%.
  • The Selling, General & Administrative Expenses for STXS have been equal to 98.71% of Gross Profit Margin.
  • The Research & Development expenses have been 38.37% of Revenue.
  • The Interest Expense is 16.67% of Operating Income.
  • The Net Earning history of STXS is -77.37% of Total Revenues.
  • Per Share Earnings over the last 24 years have been positive in 13 years.

Stereotaxis Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Health Care Equipment & Supplies
Sector: Health Care
Current Symbol: STXS
CUSIP: 85916J
Website: stereotaxis.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 2.29
Quick Ratio: 1.43

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

STXS Technical Analysis vs Fundamental Analysis

Sell
47
Stereotaxis (STXS) is a Sell

Is Stereotaxis a Buy or a Sell?

  • Stereotaxis stock is rated a Sell
    The current Stereotaxis [STXS] share price is $1.95. The Score for STXS is 47, which is 6% below its historic median score of 50, and infers higher risk than normal.